Myovant Sciences Announces U.S. Availability of ORGOVYX™ for the Treatment of Advanced Prostate Cancer
BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that ORGOVYX™ (relugolix), the first and only oral gonadotropin-releasing hormone ( …